語系:
繁體中文
English
說明(常見問題)
圖資館首頁
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Resistance to targeted therapies in ...
~
Ling, Silvia CW.
Resistance to targeted therapies in multiple myeloma
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Resistance to targeted therapies in multiple myelomaedited by Silvia CW Ling, Steven Trieu.
其他作者:
Ling, Silvia CW.
出版者:
Cham :Springer International Publishing :2021.
面頁冊數:
xvii, 154 p. :ill., digital ;24 cm.
Contained By:
Springer Nature eBook
標題:
Drug resistance in cancer cells.
電子資源:
https://doi.org/10.1007/978-3-030-73440-4
ISBN:
9783030734404$q(electronic bk.)
Resistance to targeted therapies in multiple myeloma
Resistance to targeted therapies in multiple myeloma
[electronic resource] /edited by Silvia CW Ling, Steven Trieu. - Cham :Springer International Publishing :2021. - xvii, 154 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.222196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..
1. The role of targeted therapy in multiple myeloma -- 2. Lenalidomide -- 3. Pomalidomide -- 4. Mechanisms driving resistance to proteasome inhibitors bortezomib, carfilzomib and ixazomib in multiple myeloma -- 5. Daratumumab -- 6. Elotuzumab -- 7. Histone deacetylase inhibitors -- 8. Bone targeted therapies -- 9. New targeted therapies for multiple myeloma under clinical investigation.
Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.
ISBN: 9783030734404$q(electronic bk.)
Standard No.: 10.1007/978-3-030-73440-4doiSubjects--Topical Terms:
281104
Drug resistance in cancer cells.
LC Class. No.: RC280.B6
Dewey Class. No.: 616.99418
Resistance to targeted therapies in multiple myeloma
LDR
:02863nmm a2200337 a 4500
001
605187
003
DE-He213
005
20210723092404.0
006
m d
007
cr nn 008maaau
008
211201s2021 sz s 0 eng d
020
$a
9783030734404$q(electronic bk.)
020
$a
9783030734398$q(paper)
024
7
$a
10.1007/978-3-030-73440-4
$2
doi
035
$a
978-3-030-73440-4
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC280.B6
072
7
$a
MJCL
$2
bicssc
072
7
$a
MED062000
$2
bisacsh
072
7
$a
MJCL
$2
thema
082
0 4
$a
616.99418
$2
23
090
$a
RC280.B6
$b
R433 2021
245
0 0
$a
Resistance to targeted therapies in multiple myeloma
$h
[electronic resource] /
$c
edited by Silvia CW Ling, Steven Trieu.
260
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2021.
300
$a
xvii, 154 p. :
$b
ill., digital ;
$c
24 cm.
490
1
$a
Resistance to targeted anti-cancer therapeutics,
$x
2196-5501 ;
$v
v.22
505
0
$a
1. The role of targeted therapy in multiple myeloma -- 2. Lenalidomide -- 3. Pomalidomide -- 4. Mechanisms driving resistance to proteasome inhibitors bortezomib, carfilzomib and ixazomib in multiple myeloma -- 5. Daratumumab -- 6. Elotuzumab -- 7. Histone deacetylase inhibitors -- 8. Bone targeted therapies -- 9. New targeted therapies for multiple myeloma under clinical investigation.
520
$a
Multiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.
650
0
$a
Drug resistance in cancer cells.
$3
281104
650
0
$a
Multiple myeloma
$x
Treatment.
$3
470647
650
1 4
$a
Cancer Research.
$3
273660
650
2 4
$a
Immunology.
$3
189152
700
1
$a
Ling, Silvia CW.
$3
901229
700
1
$a
Trieu, Steven.
$3
901230
710
2
$a
SpringerLink (Online service)
$3
273601
773
0
$t
Springer Nature eBook
830
0
$a
Resistance to targeted anti-cancer therapeutics ;
$v
v.4.
$3
711051
856
4 0
$u
https://doi.org/10.1007/978-3-030-73440-4
950
$a
Biomedical and Life Sciences (SpringerNature-11642)
筆 0 讀者評論
全部
電子館藏
館藏
1 筆 • 頁數 1 •
1
條碼號
館藏地
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
000000203234
電子館藏
1圖書
電子書
EB RC280.B6 R433 2021 2021
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
多媒體檔案
https://doi.org/10.1007/978-3-030-73440-4
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼
登入